Article3 Biotech2022
Bioactive compound from
Article in 3 Biotech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Exploring the Therapeutic Potential ofFood science & nutrition · 2026Article
- Genomic Insights into Adaptation ofPlants (Basel, Switzerland) · 2026Article
- Exploring the Cancer Therapeutic Potential of Traditional Medicinal Plants by Modulating the Apoptotic Pathway.BioMed research international · 2026Review
- Apoptosis Induction and MAPK Pathway Modulation by Lagerstroemia floribunda in Melanoma: Experimental and Computational Insights.Applied biochemistry and biotechnology · 2026Article
- Preparation of Diosgenin-Functionalized Gold Nanoparticles: From Synthesis to Antitumor Activities.International journal of molecular sciences · 2025Article
- Anticancer Activity of Diosgenin and Its Molecular Mechanism.Chinese journal of integrative medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study was aimed at the identification of a potential anti-cancer compound from the leaf extract of Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-022-03155-w.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.